
Early vs standard zoledronic acid treatments for prostate cancer metastatic to bone
How to Cite
OrthoEvidence. Early vs standard zoledronic acid treatments for prostate cancer metastatic to bone. ACE Report. 2020;9(8):15. Available from: https://myorthoevidene.com/AceReport/Report/6335
Randomized Controlled Trial of Early Zoledronic Acid in Men With Castration-Sensitive Prostate Cancer and Bone Metastases: Results of CALGB 90202 (Alliance)
J Clin Oncol. 2014 Apr 10;32(11):1143-50. doi: 10.1200/JCO.2013.51.6500.Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
Six hundred and forty-five patients with castration-resistant prostate cancer and bone metastases were randomized to either early administration of zoledronic acid or standard administration of zoledronic acid initiated following progression to castration-sensitive disease. The purpose was to determine whether early treatment would reduce time to developing a skeletal-related event (SREs) compared...
To view the full report, start your 30-day free trial today
No credit card required
JOIN LOGIN Forgot Password?Not sure if you want to join OrthoEvidence?
Access this report without an Account.Success, an email containing a link to access this report has been sent to your inbox.
Explore some of our unlocked reports below!

Continuing Medical Education Credits
You could be earning 0.5 CME credits for each report you read.
LEARN MORE
Please Login or Join to leave comments.